Wuhan Shuanglong Pharmaceutical Co., Ltd.

Primary objective: Using azithromycin capsules (Sumamed®, 0.25 g/capsule) produced by Pliva Croatia Ltd. as the reference preparation and azithromycin capsules (0.25 g/capsule) produced by Wuhan Shuanglong Pharmaceutical Co., Ltd. as the test preparation, the bioequivalence and relative bioavailability of the two preparations were evaluated. Secondary objective: Observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

(1) To preliminarily evaluate the effectiveness of Chailian Ganmao Granules in treating acute upper respiratory tract infection (wind-heat syndrome). (2) To explore the reasonable dosage of Chailian Ganmao Granules in treating acute upper respiratory tract infection (wind-heat syndrome) and provide a basis for Phase IIb clinical study. (3) To observe the safety of Chailian Ganmao Granules in treating acute upper respiratory tract infection (wind-heat syndrome).

1. To evaluate the effect of Jinchai Kanggan Capsule in improving the symptoms of common cold and shortening the fever course of common cold, and to explore the dosage; 2. To explore the immediate antipyretic effect of Jinchai Kanggan Capsule on common cold; 3. To explore the efficacy of Jinchai Kanggan Capsule in improving wind-heat syndrome of cold; 4. To observe the safety and adverse reactions of Jinchai Kanggan Capsule.